According to FDA prescribing information, gallbladder-related adverse events occurred in clinical trials of semaglutide for weight management (Wegovy) at rates of 2.5% versus 1.0% with placebo, and for tirzepatide (Zepbound) at rates of 2.5% versus 1.0% with placebo
H., Mathers, C., Tuomilehto, J., Nag, S., Connolly, V., & King, H
These exclusions ensured accurate determinations of baseline parameters
It is vital to help your GP distinguish between these frequently confused conditions: unlike generalised obesity (which is proportionate, affects the whole body, and responds to calorie deficits) or lymphoedema (a fluid-driven, often asymmetrical swelling that typically involves the feet), lipoedema is a distinct, nodular connective tissue disease that uniquely spares the hands and feet